Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.

Several other equities analysts also recently issued reports on the stock. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, July 10th. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.89.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.96 on Thursday. The company has a 50-day moving average of $17.97 and a 200-day moving average of $16.61. The company has a market capitalization of $20.34 billion, a price-to-earnings ratio of -46.04, a PEG ratio of 1.20 and a beta of 0.88. Teva Pharmaceutical Industries has a 52 week low of $8.06 and a 52 week high of $19.08. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at $777,285. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.55% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently modified their holdings of the business. New Covenant Trust Company N.A. bought a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $28,000. EntryPoint Capital LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. UMB Bank n.a. boosted its stake in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $48,000. Finally, Byrne Asset Management LLC bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $52,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.